SPR1020 for advanced solid tumors with DNA repair defects
Part of Cancer clinical trials.
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with an advanced solid tumor that has spread or cannot be removed by surgery.
- Your tumor must have a BRCA or other HRD gene mutation (breast, ovarian, prostate, or pancreatic cancers are priorities).
- You must have tried at least one standard treatment that no longer works, or you cannot tolerate standard therapy.
- You must be in fairly good health (ECOG 0 or 1), with adequate organ function (blood, liver, kidneys).
- You must provide tumor tissue or blood sample for genetic testing within 12 months before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This trial studies a new drug called saruparib for people with certain solid tumors that have a specific DNA repair problem (called HRD). It may help if your cancer has progressed after other treatments.
This trial tests a new drug, SYN608, in people with advanced or metastatic solid tumors, including breast and ovarian cancer, who have run out of standard treatment options. The drug targets tumors with BRCA mutations or other DNA repair problems, which may make them more sensitive to this treatment.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Hear when a new PARP Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.